GE HealthCare's fundamental outlook is anchored in a stabilizing imaging and ultrasound franchise, with recent revenue acceleration to 5.8% in 2026Q2 and a forward P/E of 14.82 suggesting reasonable valuation. However, the investment case is tempered by pronou...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has been muted but recently accelerated to 5.8% in 2026Q2, yet gross margin volatility is stark, swinging from 54.3% in 2025Q4 to 38.5% in 2026Q1, with operating margin at 14.0% in 2026Q2.
GE HealthCare Technologies Inc. presents a compelling investment case supported by a strengthening balance sheet and durable cash generation.
The company has significant valuation upside following its spinoff, with trailing and forward P/E ratios indicating potential for rerating.
GE HealthCare has received FDA clearance for Photonova Spectra, a photon-counting CT platform with advanced imaging and data processing capabilities, enabling U.S. commercial rollout.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $1.13+8.7% vs $1.04 | $5.3B+0.6% vs $5.3B |
Q2 2026 Apr 29, 2026 | $0.99-4.8% vs $1.04 | $5.1B+1.8% vs $5.0B |
Q1 2026 Feb 4, 2026 | $1.44+2.9% vs $1.40 | $5.7B+1.5% vs $5.6B |
Q4 2025 Oct 29, 2025 | $1.07+1.9% vs $1.05 | $5.1B+1.1% vs $5.1B |
Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
GE HealthCare launches an AI-powered SaaS tool that predicts hospital capacity challenges up to 72 hours ahead and recommends actions to ease bottlenecks.
GE HealthCare Technologies Inc. (GEHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.
Benchmark GEHC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for GE HealthCare Technologies Inc. (GEHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $66.27 | $29.93B | 14.56 | 4.84% | 10.1% | 21.65% | 0.21% | |
| $275.07 | $105.45B | 32.75 | 11.16% | 14.43% | 16.36% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $88.78 | $51.12B | 48.51 | 11.55% | 15.43% | 9.66% | — | |
| $24.97 | $24.41B | 23.41 | -1.04% | 6.31% | 10.02% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
GE HealthCare Technologies Inc. (GEHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
GE HealthCare Technologies Inc. (GEHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 29, 2026·SEC
Jul 23, 2026·SEC
Get notified when GEHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GE HealthCare Technologies Inc. (GEHC) stock FAQ — growth, dividends, profitability & financials explained
GE HealthCare Technologies Inc. (GEHC) reported $20.24B in revenue for fiscal year 2025. This represents a 18% increase from $17.16B in 2020.
GE HealthCare Technologies Inc. (GEHC) grew revenue by 4.8% over the past year. Growth has been modest.
Yes, GE HealthCare Technologies Inc. (GEHC) is profitable, generating $1.59B in net income for fiscal year 2025 (10.1% net margin).
Yes, GE HealthCare Technologies Inc. (GEHC) pays a dividend with a yield of 0.21%. This makes it attractive for income-focused investors.
GE HealthCare Technologies Inc. (GEHC) has a return on equity (ROE) of 21.6%. This is excellent, indicating efficient use of shareholder capital.
GE HealthCare Technologies Inc. (GEHC) generated $895.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
